A Rare Case of Uterine Leiomyosarcoma Following the Use of Tamoxifen in a Patient with Breast Cancer

Document Type : Case Report

Authors

1 Assistant Professor, Fellowship of Gynecology Oncology, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Obstetrics and Gynecology, School of Medicine, Amin Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: There is a controversial effect of Tamoxifen in reducing breast cancer recurrences, while it may increase the chance of uterine cancer occurrence. In this study, we report a rare case uterine neoplasm shortly after breast cancer treatment.Case Report: A 50-year-old woman, gravida 6 live 5 and abortion 1, with history of treated breast cancer referred with the complaint of prolonged abnormal uterine bleeding from one year before. Her breast cancer was treated by surgery and Tamoxifen therapy, which was exchanged to letrozole after her new complaint. Although, no further evaluation had been performed earlier, recently uterine myxoid leiomyosarcoma was defined.Conclusion: Tamoxifen is one of the most effective drugs in the treatment of breast cancer, but it can increase the risk of uterine cancer. In our case, after taking tamoxifen, she developed uterine leiomyosarcoma. As a result, users of this drug, especially in cases with symptoms such as abnormal bleeding, should be carefully screened for uterine cancer.

Keywords

References

  1. Costales AB, Radeva M, Ricci S. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: A National Cancer Database study. J Gynecol Oncol 2020; 31(3): e21.
  2. Meseci E, Naki MM. Prognostic factors, survival outcomes, and surgical practices when dealing with uterine sarcomas: 8 years' clinical experience. J Turk Ger Gynecol Assoc 2019; 20(3): 154-64.
  3. Parra-Herran C, Schoolmeester JK, Yuan L, Dal CP, Fletcher CD, Quade BJ, et al. Myxoid leiomyosarcoma of the uterus: A clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms. Am J Surg Pathol 2016; 40(3): 285-301.
  4. Wu TC, Hu HW, Chen TWW. Durable response to tamoxifen and metronomic cyclophosphamide in a patient with metastatic estrogen receptor-positive uterine leiomyosarcoma. J Cancer Res Pract 2020; 7(4): 174-8.
  5. Samuji M, O'Sullivan R, Shireen R. Uterine sarcoma after tamoxifen therapy for breast cancer. Ir Med J 2013; 106(8): 246.
  6. Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep 2019; 27: 1-4.

Files

History

  • Receive Date: 21 November 2020
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics